Salvine Richter

“On the launch here, how many certified neurosurgical centers do you expect to be fully trained and operationally prepared to dose commercial patients at approval, and what is the target throughput capacity here?”

“Could you speak to what you'll share with regard to preclinical data for your next-generation antibody at ASH, And how we should think about the profile of this asset versus 989 in competitors, and then also how you would position your bispecific given the similar pathway.”

“Could you just speak to when you expect genglycose to be commercially available and your expectation for the shape of the early launch curve here, and just the timeline for when patients initially engage with their healthcare provider to actually getting the treatment?”

“Can you help us further understand the grade 2 SAE? You noted that this is an expected AAV-associated risk, but how do you mitigate this risk on the forward, and how frequent are these type of events for gene therapies that leverage AAV9?”

“Just following up with the last questions, but as you, you know, just given the split of the study into separate squamous and non-squamous cohorts, and that enrollment was overall back-end loaded, how do we think about the level of follow-up in the context of the interim OS readout?”